# SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

Study · id `cardio:ct-nct04418479` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04418479](<https://clinicaltrials.gov/study/NCT04418479>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04418479

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5506 participants.

## Technical summary

Registry record NCT04418479. Randomized; no masking; primary purpose treatment. Start 2020-08-10 (actual); primary completion 2024-10-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5506 participants (enrolled count; ClinicalTrials.gov record NCT04418479, source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)
- Started: 2020-08-10 (actual) (ClinicalTrials.gov record NCT04418479, source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)
- Primary completion: 2024-10-31 (actual) (ClinicalTrials.gov record NCT04418479, source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)
- Completion: 2024-11-12 (actual) (ClinicalTrials.gov record NCT04418479, source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT04418479, source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04418479-2025-01-30`, retrieved 2026-11-18)

## The registry's words

- Brief title: SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
- Acronym: SMART-CHOICE3
- Condition: Coronary Artery Disease
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: Joo-Yong Hahn
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial (`cardio:pubmed-40174599`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clopidogrel vs Aspirin According to Diabetes Mellitus: A Prespecified Analysis of the SMART-CHOICE 3 Trial (`cardio:pubmed-42461194`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0a9e5e9dbd31fb65b5d4bfe1ac6cc2c2394804629584d2cc4c7c85eefbbe7268
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
